BioTuesdays

Category - Developments

BioTime

BioTime opens U.S. sites in dry AMD trial

BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical...

Histogenics

Histogenics cartilage data published

Histogenics (NASDAQ:HSGX) announced the online peer-reviewed publication in the Journal of Orthopaedic Research that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a...

RepliCel Life Sciences

RepliCel pursuing non-diluting grant funding

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private...

BioLight Life Sciences Ltd.

BioLight TeaRx to be used in DES trial

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi...

3D Signatures

3DS initiates HL validation program

The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company’s TeloView software platform. The purpose of Telo...